Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Receivables (2018 - 2025)

10x Genomics (TXG) has disclosed Receivables for 8 consecutive years, with $82.5 million as the latest value for Q4 2025.

  • Quarterly Receivables fell 6.75% to $82.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $82.5 million through Dec 2025, down 6.75% year-over-year, with the annual reading at $82.5 million for FY2025, 6.75% down from the prior year.
  • Receivables hit $82.5 million in Q4 2025 for 10x Genomics, down from $96.6 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $119.1 million in Q2 2025 to a low of $52.5 million in Q1 2025.
  • Historically, Receivables has averaged $85.5 million across 5 years, with a median of $84.4 million in 2021.
  • Biggest five-year swings in Receivables: skyrocketed 162.61% in 2021 and later plummeted 42.45% in 2025.
  • Year by year, Receivables stood at $85.3 million in 2021, then grew by 22.24% to $104.2 million in 2022, then grew by 10.19% to $114.8 million in 2023, then decreased by 22.96% to $88.5 million in 2024, then dropped by 6.75% to $82.5 million in 2025.
  • Business Quant data shows Receivables for TXG at $82.5 million in Q4 2025, $96.6 million in Q3 2025, and $119.1 million in Q2 2025.